1. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets
   Evan Rosenbaum et al, 2020, Modern Pathology CrossRef
2. PARP inhibitors as precision medicine for cancer treatment
   Yi Du et al, 2017, National Science Review CrossRef
3. Exploiting DNA repair defects in colorectal cancer
   Nicole M. Reilly et al, 2019, Molecular Oncology CrossRef
4. PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
   Changjiang Qin et al, 2022, Cell Death & Disease CrossRef
5. Tissue-Based Markers as a Tool to Assess Response to Neoadjuvant Radiotherapy in Rectal Cancer—Systematic Review
   Edgaras Smolskas et al, 2022, International Journal of Molecular Sciences CrossRef
6. Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis
   Yan Wang et al, 2021, Mutagenesis CrossRef
7. Germline Variants in DNA Repair Genes, Diagnostic Radiation, and Risk of Thyroid Cancer
   Jason E. Sandler et al, 2018, Cancer Epidemiology, Biomarkers & Prevention CrossRef
8. Electrophoretic mobility shift assays implicate XRCC2:rs3218550C>T as a potential low-penetrant susceptibility allele for sporadic breast cancer
   Nirmala D. Sirisena et al, 2019, BMC Research Notes CrossRef
9. Genetic determinants of sporadic breast cancer in Sri Lankan women
   Nirmala Dushyanthi Sirisena et al, 2018, BMC Cancer CrossRef
10. XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy
    Chang-Jiang Qin et al, 2015, Oncotarget CrossRef